EUCTR2011-000045-20-GB进行中（未招募）1 期
Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study) - SIRE
RECORDATI S.p.A0 个研究点目标入组 0 人开始时间: 2011年3月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Clinical diagnosis of BPH by the urologist; - Male subjects aged 60 years or older; - IPSS total score =12 at Visit 1 (Screening) and 2 (Baseline); - Able to comply with protocol procedures; - Written informed consent obtained before beginning any investigational procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Hypersensitivity to the active substance or to any of the excipients; - Patients for whom cataract surgery is scheduled; - History of orthostatic hypotension or syncope; - Moderate or severe renal impairment (CLCR <50 ml/min, as estimated by the Cockcroft Gault formula); - Severe hepatic impairment; - Concomitant use of other a-adrenoreceptor antagonists or natural/herbal products known to have an effect on LUTS (e.g. saw palmetto - serenoa serulata/repens) . Patients already on treatment with those drugs may be enrolled after a 4 week wash-out period before Visit 2 (baseline); - Concomitant use with potent CYP3A4 inhibitors, such as ketoconazole, itraconazole or ritonavir (possible PK interaction); - Prostate cancer; - History of prostate or bladder neck surgery, including TURP, TUNA, laser or other minimally invasive therapy; - Active urinary tract infection; - Acute or recurrent prostatitis (more than 3 times in the last year); - History of neurological disease that may affect bladder function; - Unstable cardiovascular or cerebrovascular disease (including acute myocardial infarction, unstable angina pectoris, by-pass, PTCA, congestive heart failure class III-IV, stroke, transient ischemic attack and episodes of cardiac arrhythmia requiring treatment in the last 6 months); - History or current evidence of drug or alcohol abuse within the last 12 months; - Participation in a study involving the administration of an investigational compound within the past 30 days; - Any other condition which, in the investigator's judgement, renders the subject unable to complete the study or increases the risk to the subject or which prevents optimal participation in achieving the objectives of the study.
研究者
相似试验
进行中（未招募）
1 期
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-ESRECORDATI S.p.A
进行中（未招募）
1 期
Effectiveness and safety of silodosin in the treatment of patients with benign prostatic hyperplasia.Benign prostatic hyperplasia.EUCTR2011-000045-20-RORECORDATI S.p.A
进行中（未招募）
不适用
Effectiveness and safety of silodosin in the treatment of LUTS in patients with benign prostatic hyperplasia: a European phase IV clinical study (the Silodosin in Real-life Evaluation study) - SIREBenign prostatic hyperplasia.MedDRA version: 13.1Level: PTClassification code 10004446Term: Benign prostatic hyperplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2011-000045-20-HURECORDATI S.p.A1,000
进行中（未招募）
不适用
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-PTRECORDATI S.p.A1,000
进行中（未招募）
不适用
A clinical study, which evaluates the effectiveness and the safety of a new medication for prostatic hyperplasia, silodosin, when administered under normal conditions of use in a wide European population.EUCTR2011-000045-20-DERECORDATI S.p.A1,000